Author

Xing Liu

Institutions: Xuzhou Central Hospital, Southeast University

Observed institutions: Xuzhou Medical College, Xuzhou Central Hospital, Southeast University

ORCID: 0000-0001-6059-3686

Observed ORCID: 0000-0001-6059-3686

OpenAlex ID: A5040910237

Lutetium Lu 177 vipivotide tetraxetan for prostate cancer

2023 · Xing Liu, Gao-Chuan Fang, et al. · Drugs of today · 14

Co-delivery of Siape1 and Melatonin by 125I-loaded PSMA-targeted Nanoparticles for the Treatment of Prostate Cancer

2023 · Ying Liu, Lin Hao, et al. · Recent Patents on Anti-Cancer Drug Discovery · 8

Serial H&E Pathology Reveals Progression‐Associated Nuclear Size Drift as a Longitudinal Digital Readout of Bladder Cancer Evolution

2026 · Xing Liu, Zhen‐Duo Shi, et al. · Advanced Science

Mechanistic analysis on epigenetic programming of tumor drug resistance

2026 · Xiao-Xiao Han, Kun Pang, et al. · Drug Resistance Updates

[Analysis the influencing factors and risk warning of the therapeutic efficacy of multi plane low temperature plasma radiofrequency ablation for OSAHS].

2025 · Xing Liu, Kaiwei Dong, et al. · PubMed

Bladder Cancer Recurrence Prediction: Using CT Scans and Convolutional Neural Networks with Transfer Learning (Preprint)

2022 · Xing Liu, Jian Guo, et al.

Works count: 6

Citation count: 22

H-index: 2

I10-index: 1